A Multicenter Retrospective Study on the Prognosis of Stage III Unresectable Mutant Non-Small Cell Lung Cancer With Tyrosine Kinase Inhibitors Therapy

BACKGROUND: For unresectable stage III non-small cell lung cancer (NSCLC), concurrent chemoradiotherapy is nowadays the standard treatment. Patients with advanced NSCLC harboring driver-gene mutations benefit from Tyrosine Kinase Inhibitors (TKIs) Therapy. In a real-world setting, there is room for...

全面介紹

Na minha lista:
書目詳細資料
發表在:Front Oncol
Main Authors: Wu, Ranpu, Yu, Shaorong, Ye, Jinjun, Wang, Yimin, Zhao, Zhiting, Liu, Hongbing, Song, Yong
格式: Artigo
語言:Inglês
出版: Frontiers Media S.A. 2021
主題:
Oncology
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC8311792/
https://ncbi.nlm.nih.gov/pubmed/34322390
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.692703
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍